Shopping Cart
- Remove All
- Your shopping cart is currently empty
Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo. Copper histidine is administered orally for the treatment of Menkes disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $76 | In Stock | |
5 mg | $177 | In Stock | |
10 mg | $260 | In Stock | |
25 mg | $506 | In Stock | |
50 mg | $690 | In Stock | |
100 mg | $982 | In Stock | |
500 mg | $1,970 | In Stock |
Description | Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo. Copper histidine is administered orally for the treatment of Menkes disease. |
In vitro | Copper histidine (10 lmol/L) inhibited cellular uptake of oxaliplatin mediated by Ctr1 in HEK293 cells overexpressing rat Ctr1.[1] |
Molecular Weight | 217.69 |
Formula | C6H8CuN3O2 |
Cas No. | 77280-83-2 |
Smiles | O=C1[O-][Cu+2]2[N]3(C(C[C@@]1([NH2]2)[H])=CN=C3)[H] |
Relative Density. | no data available |
Storage | Shipping with blue ice. | ||||||||||
Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) (1.97 mM) DMSO: < 1 mg/mL (insoluble) | ||||||||||
Solution Preparation Table | |||||||||||
H2O
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.